Plain-English translation of NCT05901818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to Parkinson's disease using autologous induced neural stem cell-derived dopaminergic precursor cells—brain cells grown from your own blood that are designed to replace dopamine-producing neurons lost to the disease. Researchers will transplant these cells directly into your brain and monitor whether the treatment is safe and whether it helps reduce your Parkinson's symptoms over 12 months.
Parkinson's disease happens when dopamine-producing brain cells gradually die, and current medications can only manage symptoms—they don't replace the lost cells. This trial explores whether transplanting new dopamine-producing cells grown from a patient's own blood could offer a more direct way to treat the disease.
You likely qualify if…
You likely don't qualify if…
You would undergo a minor procedure to harvest blood cells, which are then sent to a lab to be reprogrammed into dopamine-producing brain cells over several weeks. Once ready, you would receive brain surgery to transplant these cells into the specific brain region affected by Parkinson's. After transplantation, you would return for follow-up visits over 12 months, including brain imaging scans and symptom assessments, to determine whether the cells survive and whether your Parkinson's symptoms improve.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China